Physician profile
Fatima Ali
NPI 1013366368
$21,624.20
in general payments reported to CMS, 2019-2025
18 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $101 · 2021: $236 · 2022: $10K · 2023: $10K · 2024: $534 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $10K · Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,000.00 |
| Food and Beverage | $956.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20,000.00 | 2022-2023 | |
| Pulmonx Corporation | $371.71 | 2024-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Glaxosmithkline, LLC. | $261.26 | 2019-2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $253.84 | 2021-2024 | Tezspire |
| Steris Corporation | $246.70 | 2023-2025 | |
| Intuitive Surgical, INC. | $128.98 | 2022-2023 | Da Vinci Surgical System |
| Philips North America LLC | $115.68 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.48 | 2024 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $34.64 | 2024 | Glassia |
| Amgen INC. | $30.03 | 2024 | Tezspire |
| Impulse Dynamics (USA) INC. | $26.62 | 2022 | |
| Insmed, INC. | $18.74 | 2024 | Arikayce |
| Novartis Pharmaceuticals Corporation | $17.94 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.07 | 2024 | Nuzyra |
| Teleflex LLC | $14.79 | 2023 | Manta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14.71 | 2024 | Dupixent |
| Mylan Specialty L.P. | $13.75 | 2024 | Yupelri |
| Bsn Medical INC | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.